Video Presentation

VIDEO: Open Orphan’s Maurice Treacy details pharma services firm’s ambitious growth plans in exclusive ValueTheMarkets presentation (ORPH)

31 Oct 2019 | by: Patricia Miller

On Wednesday, ValueTheMarkets’ Ben Turney hosted Maurice Treacy, director at rare disease and orphan drug-focused pharma services company Open Orphan, in a recorded presentation and interview.

Treacy began by providing shareholders and potential investors with a detailed run through his firm’s robust range of services including its Virtual Rep database and its Genomic Health Data platform. He then went on to cover the opportunity on offer in Europe’s fast-growing orphan drug market and Open Orphan’s plans to consolidated the region’s fragmented pharma services sector through acquisitions.

Following an initial presentation, Treacy took a number of audience questions. These spanned a number of interesting topics such as the background of Open Orphan’s board, the company’s competition, its growth strategy, and the potential for a re-rate in its valuation.

For a full recording of the presentation, please see below:, Digitonic Ltd (and our owners, directors, officers, managers, employees, affiliates, agents and assigns) are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

  • Digitonic Ltd, the owner of, has been paid for the production this piece by the company or companies mentioned above.

RNS Responses

Top Tin companies to invest in

Tin is vital for electronics, so it’s experiencing soaring demand along with repressed supply. Here are some tin-related investment ideas.

When is Databricks going public?

Databricks ranks among the highest valued private tech firms and is generating plenty of hype ahead of a likely float, but when will this take place?